
|Articles|March 1, 2004
Betamethasone valerate effective for short-term stasis dermatitis
Waikoloa, Hawaii -- Pilot study results indicate that 0.12 percent betamethasone valerate foam is more effective than vehicle alone for short-term stasis dermatitis treatment. "This topical therapy can lead to improved health-related quality of life in these patients," said Alexa Boer Kimball, M.D., assistant professor and director, dermatology clinical trials, Stanford University School of Medicine.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
5


















